The Replication Study that will be published upon completion of data collection will include a thorough discussion of reasons the experiment could have succeeded or failed to replicate, including variation in the efficacy of AOM.
Overall, we will spend a minimum of six months working in each of the two microsystems using a multi-method approach; data collection will include a minimum of 15 face-to-face interviews, observations of organisational processes and documentary analysis.
Data collection will include information on citations and identified tools.
Future data collection will include assisted means to function such as mobility aids and carers.
Data collection will include semi-structured and informal interviews, naturalistic observation of various processes and people, and document analysis.
Data collection will include (1) participant interviews, (2) capture of clinical data from medical records and (3) linkage to MBS/PBS records.
Baseline data collection will include age, gender, body mass index, usual ACT if previously prescribed and MMRC scale for dyspnoea [ 20].
At baseline, data collection will include age, gender, body mass index, past medical history, smoking history, use of oxygen therapy, current pharmological treatment and all of the following outcome measures.
Baseline descriptive data collection will include age, gender, social, working and smoking history, admission diagnosis, hand/leg dominance, comorbidities as determined by the Functional Comorbidity Index and Charlson Comorbidity Index, severity of illness scoring and SAS Score.
Data collection will include observations of vaccination day, semi-structured interviews with teachers, school nurses, immunisation nurses and parents, and semi-structured focus groups with students to provide a more in-depth understanding of the mechanisms for change promoted by the intervention.
